CLOV (Managed Health Care) Stock Valuation & Fair Value Significantly overvalued
CLOV (Managed Health Care) trades at a blended P/E of 164.0, about 152% above its historical normal valuation, with a forward growth estimate of 89.9% and a PEG of 1.82. Analysts' one-year estimates have been hit 25% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
Valuation flags
- Overvalued by 152%
Frequently asked questions
Is CLOV overvalued?
At a blended P/E of 164.0 versus its historical normal P/E of 65.0, CLOV trades about 152% above its typical valuation, with a PEG of 1.82 on 89.9% forward growth. tickerseer currently rates it significantly overvalued.
What is CLOV's fair value and PEG?
CLOV trades at a blended P/E of 164.0 against a historical normal P/E of 65.0, a PEG of 1.82, and a forward growth estimate of 89.9%.
Has tickerseer's rating of CLOV changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
Industry: Managed Health Care. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.